| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.1 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.2 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.065 | 0.2 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.081 | 0.2 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |